**Author details**

Fong-Fu Chou1 \* and Jin-Bor Chen<sup>2</sup> \*

1 Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan

2 Department of Nephrology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan

\*Address all correspondence to: choulu@ms4.hinet.net and chenjb1019@gmail.com

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**109**

*Severe Hypocalcemia after Total Parathyroidectomy Plus Autotransplantation for Secondary…*

et al. An epidemiologic analysis of parathyroidectomy in chronic dialysis patients. The Okinawa dialysis study group. Nihon Jinzo Gakkai Shi.

[9] Akaberi S, Clyne N, Sterner G, Rippe B, Reihnér E, Wagner P, et al. Temporal trends and risk factors for parathyroidectomy in the Swedish dialysis and transplant population a nationwide, population-based study 1991-2009. BMC Nephrology. 2014;**15**:75

[10] Kim SM, Long J, Montez-Rath ME,

Chertow GM. Rates and outcomes of Parathyroidectomy for secondary hyperparathyroidism in the United States. Clinical Journal of the American Society of Nephrology.

[11] Yin SM, Chou FF, Wu SC, Chi SY. Applying preoperative dipyridamole thallium-201 scintigraphy for preventing cardiac mortality and complications for patients with secondary hyperparathyroidism undergoing parathyroidectomy. Asian Journal of Surgery. 2018;**41**(3):229-235

[12] van der Plas WY, Engelsman AF, Umakanthan M, Mather A, Sidhu SB, Delbridge LW, et al. Treatment strategy of end stage renal disease-related hyperparathyroidism before, during, and after the era of calcimimetics. Surgery. 2019;**165**(1):135-141

[13] Chou FF, Chan HM, Huang TJ, Lee CH, Hsu KT. Autotransplantation

[14] Yang M, Zhang L, Huang L, Sun X,

Ji H, Lu Y. Factors predictive of critical value of hypocalcemia after total parathyroidectomy without

of parathyroid glands into subcutaneous forearm tissue for renal hyperparathyroidism. Surgery.

1998;**124**(1):1-5

Leonard MB, Norton JA,

2016;**11**(7):1260-1267

1996;**38**(7):309-313

*DOI: http://dx.doi.org/10.5772/intechopen.92976*

[2] Alfieri C, Malberti F, Mazzaferro S, Gallieni M, Russo D, Messa P, et al. Hyperphosphatemia in dialysis: which binder? Giornale Italiano di Nefrologia.

[3] Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, et al. A comparison of the calcium-free phosphate binder sevelamer

hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. American Journal of Kidney Diseases. 1999;**33**(4):694-701

[4] Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clinical Journal of the American Society of Nephrology. 2018;**13**(6):952-961

[5] Rroji M, Spasovski G. Calcimimetics versus parathyroidectomy: What is preferable? International Urology and Nephrology. 2018;**50**(7):1271-1275

[7] Shireman TI, Almehmi A, Wetmore JB, Lu J, Pregenzer M, Quarles LD. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexibledose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. American Journal of Kidney Diseases. 2010;**56**(6):1108-1116

[8] Tokuyama K, Iseki K, Yoshi S, Yoshihara K, Nishime K, Uehara H,

[6] Cozzolino M, Elli F, Carugo S, Ciceri P. Secondary hyperparathyroidism in end-stage renal disease: No longer a matter for surgeons? Blood Purification.

2016;**42**(1):44-48

[1] Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney International.

**References**

2010;**77**(3):232-238

2018, 2018;**35**(5)

*Severe Hypocalcemia after Total Parathyroidectomy Plus Autotransplantation for Secondary… DOI: http://dx.doi.org/10.5772/intechopen.92976*
